Boehringer Ingelheim Dealt New Blow In Nearly Two Years Of Review For Pradaxa In Australia
This article was originally published in The Pink Sheet Daily
Australia’s Health Ministry calls for additional study of anticoagulant Pradaxa, dealing a fresh blow to Boehringer Ingelheim’s hopes of getting listed on the national reimbursement program nearly two years after initial regulatory approval.
You may also be interested in...
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.
Pharmaceutical giant Boehringer Ingelheim took on the Australian federal government Nov. 2, calling for the approval of Boehringer's new anti-coagulant drug Pradaxa (dabigatran) for the country's Pharmaceutical Benefits Scheme
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government